Risk factors and drugs in the treatment of hypertension.
BACKGROUND
A wide range of drug classes, frequently including centrally acting agents, has been used in clinical trials in hypertension which have shown benefit. Although therapy has clearly limited the complications of hypertension, further improvement is needed, especially concerning coronary artery disease.


CONCLUSIONS
Future interest therefore centres on drugs that do not worsen diabetes mellitus, do not cause dyslipidaemia, or induce potassium loss, while not provoking drowsiness, depression, other troublesome side-effects, or being associated with rebound hypertension when stopped. The centrally acting imidazoline agonists merit detailed study in this regard.
Robertson
J I
JI
Department of Medicine, Chinese University, Hong Kong.
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D054755:Imidazoline Receptors; D011955:Receptors, Drug / Q000819:agonists; D012307:Risk Factors
D000959:Antihypertensive Agents; D054755:Imidazoline Receptors; D011955:Receptors, Drug